PT - JOURNAL ARTICLE AU - Moni, Merlin AU - Madathil, Thushara AU - Sathyapalan, Dipu T AU - Menon, Veena AU - Gutjahr, Georg AU - Edathadathil, Fabia AU - Sureshkumar, Deepthi AU - Prasanna, Preetha AU - Jose, Soumya AU - Jerome, Roshni AU - Krishnan, Ajai AU - Pillai, Indulekha C AU - Kumar, Geetha AU - Nair, Bipin AU - Jayant, Aveek TI - A Feasibility Trial to Evaluate the Composite Efficacy of Inhaled Nitric Oxide in the Treatment of Covid 19 Pneumonia : Impact on Viral Load and Clinical Outcomes AID - 10.1101/2021.04.15.21255300 DP - 2021 Jan 01 TA - medRxiv PG - 2021.04.15.21255300 4099 - http://medrxiv.org/content/early/2021/04/20/2021.04.15.21255300.short 4100 - http://medrxiv.org/content/early/2021/04/20/2021.04.15.21255300.full AB - Background Hypoxic patients with Covid 19 pneumonia are at high risk of adverse outcomes. Inhaled Nitric Oxide (iNO) inhibits viral entry and replication of SARS-CoV2 and in vivo proof of its antiviral actions is unavailable to date. This feasibility study was conducted to test the antiviral effects of iNO and to describe clinical outcomes.Trial design and Methods The phase II open label, randomised controlled feasibility trial(ISRCTN 16806663) conducted at a South Indian tertiary care referral centre, recruited COVID-19 pneumonia patients with hypoxic respiratory failure and allocated them into iNO cases and control groups(1:1). iNO was administered as pulses for 30 minutes for three consecutive days at 12-hour intervals in cases, in addition to standard of care received by the control group. The primary outcome was decline in viral load, as defined by a surrogate change in the RT-PCR cycle threshold. The co-primary clinical outcome was time to improvement of >2 points on the WHO Ordinal Scale(WOS).Results Among the 29 patients enrolled, 14 iNO cases and 11 controls completed the study protocol. Longitudinal analysis revealed a significant difference in the decline (p <0.002, N= 23) in viral load among the iNO cases compared to controls. The proportion of patients achieving 2-point improvement in the WOS within 14 days of randomisation was significantly higher in the iNO cases (n=11, 79%), as compared to the controls (n=4, 36%) (p=0.05).Conclusions Our study demonstrated significant improvement in virological and clinical outcomes among patients with adjunct iNO therapy and no adverse effects were reported.Competing Interest StatementThe authors have declared no competing interest.Clinical TrialISRCTN 16806663Funding StatementThe work was supported by the collaborating centre, the Amrita School of Biotechnology, Amrita Vishwa Vidyapeetham.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Drugs Controller General India Institutional Ethics Committee, Amrita Institute of Medical Science All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe datasets generated during and/or analysed during the current study are available from the corresponding author on reasonable request.